Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Leukemia & Lymphoma|April 28, 2016
Use of class I histone deacetylase inhibitor romidepsin in combination regimensAdam Petrich, Chadi NabhanJournal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Brentuximab vedotin in patients with relapsed HIV-related lymphomaMitul Gandhi, Adam PetrichLeukemia & Lymphoma|February 24, 2016
The evolving role of lenalidomide in non-Hodgkin lymphomaNatalie Galanina, Adam Petrich, Chadi NabhanCancer|October 6, 2010
Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patternsAdam Petrich, Soung Ick Cho, Henny BillettLeukemia & Lymphoma|January 19, 2008
Phase II study of doxercalciferol for the treatment of myelodysplastic syndromeAdam Petrich, Brad Kahl, Howard Bailey, et al.JAMA Oncology|April 8, 2016
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell LymphomaM Estela Martinez-Escala, Timothy M Kuzel, Jason B Kaplan, et al.CPT: Pharmacometrics & Systems Pharmacology|November 2, 2023
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage developmentYasong Lu, Shuang Liang, Ying Hong, et al.Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.Pageof 2